Quantamatrix announced on the 15th that its rapid antimicrobial susceptibility testing equipment for sepsis treatment, ‘dRAST,’ has been adopted by Gustave Roussy Hospital in France, one of the world’s top three cancer specialty hospitals and Europe’s leading cancer center, and has begun full-scale application in testing.
Gustave Roussy Hospital in France is one of the world’s top three specialized hospitals in the field of cancer and oncology. With state-of-the-art facilities serving over 46,000 patients annually, it provides the highest quality medical care as a specialized hospital.
A representative of Quantamatrix’s French branch stated, “Cancer patients have an increased risk of sepsis due to weakened immune systems, so timely and appropriate antibiotic treatment is very important. The dRAST system can reduce the time required for antimicrobial susceptibility testing by up to 50 hours, which is expected to improve the survival rate of sepsis patients who die acutely.”
He added, “By introducing the dRAST system as a routine clinical test, clinicians will be able to treat cancer patients promptly, thereby enhancing clinical value. Furthermore, it is expected to contribute to reducing unnecessary medical expenses for both patients and the nation.”
The company explained that the adoption of dRAST by Gustave Roussy Hospital is particularly significant as a milestone achievement in France, where Quantamatrix’s European branch conducts direct sales. Since 2021, starting with Limbach Group, Germany’s largest medical testing institution, installations have been expanding throughout the European market, including the UK and Switzerland, via a network of distributors.
In August of last year, Quantamatrix’s European branch succeeded in winning a contract with UniHA (Union des H?pitaux pour les Achats), the purchasing organization that accounts for over 90% of the public hospital procurement market in France, opening the door for large-scale entry into the French market. Following the adoption by Gustave Roussy Hospital, there is reason to expect an acceleration in the expansion of ‘dRAST’ in France. France is also home to the Pasteur Institute headquarters, with a 130-year history specializing in microbiological research, making it a stronghold of the microbiological diagnostic market with advanced clinical microbiology diagnostics.
Quantamatrix’s ‘dRAST’ quickly assists in diagnosing and treating sepsis patients by identifying and prescribing optimal antibiotics. Ultimately, it is equipment that contributes to saving the lives of sepsis patients. Using positive blood culture samples without a separate isolation culture process, it reduces the antimicrobial susceptibility testing time, which previously took over 60 hours, by 30 to 50 hours. Additionally, it is the first antimicrobial susceptibility testing equipment to adopt artificial intelligence (AI) deep learning technology. It rapidly interprets various bacterial growth patterns observed in clinical situations, enabling the identification of the optimal antibiotic.
A Quantamatrix official said, “The installation of dRAST at one of the world’s top three cancer specialty hospitals with a high clinical standard is very meaningful. Following the UniHA contract, several French hospitals have signed adoption agreements, and installations are currently underway.”
He continued, “The dRAST solution has been recognized for its clinical significance and is gradually expanding its influence in Europe, a major market. With a solid sales foundation established as of 2023, we expect to achieve substantial growth going forward.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
